SEC Filing Summary: Aadi Bioscience, Inc. (8-K)
Business Context and Reporting Period
This Form 8-K was filed by Aadi Bioscience, Inc. on March 17, 2022. The filing serves to announce the company's financial results for the fiscal quarter and full year ended December 31, 2021. The registrant is an emerging growth company incorporated in Delaware, with its principal executive offices in Pacific Palisades, California.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the press release attached as Exhibit 99.1, which is incorporated by reference but not detailed in the body of this 8-K document.
Material Changes
No specific material changes versus prior periods are quantified in this filing text. The document solely references the issuance of a press release containing the comparative financial data for the period ended December 31, 2021.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer stating that the information furnished in Item 2.02 and Item 9.01 (including the attached press release) is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934. Consequently, this information is not subject to the liabilities of that section nor incorporated by reference into other filings unless expressly stated. No specific guidance, outlook, or risk factors are detailed in the text of this 8-K.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated March 17, 2022) for specific revenue, net loss, and cash position figures.
- Verify the company's cash runway and burn rate as disclosed in the attached press release.
- Confirm any updates to clinical trial progress or regulatory milestones mentioned in the full press release.
- Check for any forward-looking statements or guidance provided in the referenced exhibit.